ArticleJournal of the neurological sciences2021
Immunosuppression in chronic autoimmune neurological disorders during the COVID-19 pandemic.
Article in Journal of the neurological sciences, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 4 syntheses or guidelines pooled it, 42 citations in OpenAlex.
- Systematic review of risk of SARS-CoV-2 infection and severity of COVID-19 with therapies approved to treat multiple sclerosis.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2022Pooled it
- The prevalence of COVID-19 infection in patients with multiple sclerosis (MS): a systematic review and meta-analysis.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2021Pooled it
- COVID-19 Among Patients With Multiple Sclerosis: A Systematic Review.Neurology(R) neuroimmunology & neuroinflammation · 2021Pooled it
- Risk factors of severe COVID-19 in people with multiple sclerosis : A systematic review and meta-analysis.Revue neurologiquePooled it
- A comprehensive review of methodologies and application to use the real-world data and analytics platform TriNetX.Frontiers in pharmacology · 2025Review
- The Impact of COVID-19 Vaccination and Infection on the Exacerbation of Myasthenia Gravis.Vaccines · 2024Article
- COVID-19 in patients with myasthenia gravis: a single-center retrospective study in China.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2024Article
- A comprehensive review of COVID-19 symptoms and treatments in the setting of autoimmune diseases.Virology journal · 2023Review
- Characteristics of COVID-19 in patients with multiple sclerosis.Multiple sclerosis and related disorders · 2022Article
- A bibliometric analysis of COVID-19 publications in neurology by using the visual mapping method.Frontiers in public health · 2022Article
- COVID-19 infection and hospitalization rate in Iranian multiple sclerosis patients: What we know by May 2021.Multiple sclerosis and related disorders · 2022Article
- Secondary Immunodeficiency and Risk of Infection Following Immune Therapies in Neurology.CNS drugs · 2021Review
- Neuromuscular complications of coronavirus disease-19.Current opinion in neurology · 2021Review
- Special Considerations in the Management of Autoimmune Hepatitis in COVID-19 Hotspots: A Review.Journal of clinical and translational hepatology · 2021Review
- Continued Underutilization of stroke care during the COVID-19 pandemic.Brain, behavior, & immunity - health · 2021Article
- The outcome of a national MS-Covid-19 study: What the Turkish MS cohort reveals?Multiple sclerosis and related disorders · 2021Article
- COVID-19 outcomes among people with intellectual and developmental disability in California: The importance of type of residence and skilled nursing care needs.Disability and health journal · 2021Article
- Knowledge, attitudes, and impact of COVID-19 pandemic among neurology patients in Jordan: a cross-sectional study.The Egyptian journal of neurology, psychiatry and neurosurgery · 2021Article
- Article
- To Be or Not To Be Vaccinated: That Is a Question in Myasthenia Gravis.Frontiers in immunologyReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 3 institutions in 1 country.
Funding
Abstract
objectiveTo study the risk of acquiring Corona Virus Disease 2019 (COVID-19) and its outcomes in patients on immunosuppressive therapy (IST) for chronic autoimmune neuromuscular disorders (aNMD) and multiple sclerosis (MS).
methodsWe used TriNetX, a global health collaborative clinical research platform collecting real-time electronic medical records data, which has one of the largest known global COVID-19 database. We included patients with chronic autoimmune neuromuscular disorders (aNMD) [myasthenia gravis (MG), inflammatory myositis, and chronic inflammatory neuropathies (CIN)] and MS, based on the International Classification of Disease-10 (ICD-10) coding for one year before January 20th, 2020. We examined the use of IST, rate of COVID- 19, hospitalization, intubation, and mortality among the patients with aNMD and MS.
resultsA total of 33,451 patients with aNMD and 42,899 patients with MS were included. Among them, 111 (0.33%) patients with aNMD and 115 patients (0.27%) with MS had COVID-19. About one third of them required hospitalization. IST did not appear to have a significant impact on overall infection risk in either group; however, risk of hospitalization for immunosuppressed patients with aNMD was higher (Odds ratio 2.86, p-value 0.011).
conclusionsIST use does not appear to make patients with aNMD and MS more vulnerable to COVID-19. IST may be continued during the pandemic, as previously suggested by expert opinion guidelines. However, it is important to consider individualizing immunotherapy regimens in some cases. Additional physician reported registry-based data is needed to further confirm these findings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.